Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/28/24
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 MilestonesGlobeNewsWire • 01/04/24
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBMGlobeNewsWire • 12/13/23
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/06/23
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535GlobeNewsWire • 10/14/23
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/04/23
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung CancerGlobeNewsWire • 09/11/23
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/23
Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer UpdateSeeking Alpha • 08/03/23
Black Diamond Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewsWire • 06/30/23
Black Diamond Therapeutics Announces Proposed Public Offering of Common StockGlobeNewsWire • 06/28/23
Black Diamond Therapeutics stock rockets after positive trial data shows anti-tumor activityProactive Investors • 06/27/23
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation FamiliesGlobeNewsWire • 06/27/23
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development OfficerGlobeNewsWire • 06/13/23
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/23
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology DaysGlobeNewsWire • 04/18/23
Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual MeetingGlobeNewsWire • 04/17/23
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/09/23